NRD
PSTX

Nebula Research & Development’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Nebula Research & Development’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,197
Closed -$31.4K – 466
2023
Q1 		$31.4K Buy
+10,197
New +$61.1K 0.06% 219

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Nebula Research & Development's PSTX Position: Q2 2023 in Review

Nebula Research & Development sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2023, closing a stake of 10,197 shares — an estimated $31.4K sold.

Nebula Research & Development first reported a position in PSTX in Q1 2023 and held it in 1 quarter. The position peaked at $31.4K in Q1 2023. 94 funds tracked by Wall St. Rank hold PSTX as of Q2 2023.

  • Nebula Research & Development reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Nebula Research & Development sold 10,197 Poseida Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $31.4K.
  • Nebula Research & Development first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Nebula Research & Development's Poseida Therapeutics, Inc. Common Stock position peaked at $31.4K in Q1 2023.
  • 94 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Nebula Research & Development's 13F filing for Q2 2023, filed 14 Aug 2023.